Amendment Letter to Study Funding Agreement between Hollis-Eden Pharmaceuticals, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc.
Hollis-Eden Pharmaceuticals, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc. have agreed to amend their existing Study Funding Agreement dated June 17, 2003. This letter changes the wording of Section 8.1(c) of the original agreement, with the specific details omitted for confidentiality. All other terms of the original agreement remain unchanged and in effect. The amendment is effective as of December 2005, as acknowledged by both parties' representatives.
EXHIBIT 10.52
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities And Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
November 30, 2005
Chris Penland, Ph.D.
Cystic Fibrosis Foundation Therapeutics, Inc.
6931 Arlington Road
Bethesda, MD 20814
Dear Dr. Penland:
The purpose of this letter (“Letter”) is to amend the Study Funding Agreement, between the undersigned parties, dated June 17, 2003, as amended (the “Agreement”). By signing below, the undersigned parties agree to the following:
In Section 8.1(c) of the Agreement, [ * ] shall be replaced with [ * ].
All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect.
| HOLLIS-EDEN PHARMACEUTICALS, INC. | ||||||||
| By: | /s/ ERIC J. LOUMEAU | Date: December 13, 2005 | ||||||
| Eric J. Loumeau Vice President, General Counsel | ||||||||
Agreed to and Acknowledged by:
| CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | ||||||||
| By: | /s/ ROBERT J. BEALL | Date: December 9, 2005 | ||||||
| Robert J. Beall, Ph.D. President and CEO | ||||||||
